Sumicad, Merlyn A.
HRN: 26-43-31 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
12/28/2024
CEFUROXIME 1.5GM (VIAL)
12/28/2024
12/31/2024
IV
1.5gm 3 Doses
Q8
Post CS
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft TissueIntra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes